Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes (NCT05478707) | Clinical Trial Compass
SuspendedPhase 2
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Stopped: Institution transfer
United States47 participantsStarted 2023-10-05
Plain-language summary
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Who can participate
Age range18 Years – 40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.